Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
D Lavacchi, F Mazzoni, G Giaccone - Drug design, development …, 2019 - Taylor & Francis
Systemic treatment of advanced non-small cell lung cancer (NSCLC) has undergone
remarkable changes in the last decade, with the introduction of targeted therapies and …
remarkable changes in the last decade, with the introduction of targeted therapies and …
Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
D Lavacchi, F Mazzoni, G Giaccone - Drug Design, Development …, 2019 - dovepress.com
Systemic treatment of advanced non-small cell lung cancer (NSCLC) has undergone
remarkable changes in the last decade, with the introduction of targeted therapies and …
remarkable changes in the last decade, with the introduction of targeted therapies and …
[HTML][HTML] Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
D Lavacchi, F Mazzoni, G Giaccone - Drug Design, Development …, 2019 - ncbi.nlm.nih.gov
Systemic treatment of advanced non-small cell lung cancer (NSCLC) has undergone
remarkable changes in the last decade, with the introduction of targeted therapies and …
remarkable changes in the last decade, with the introduction of targeted therapies and …
Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
D Lavacchi, F Mazzoni… - Drug design …, 2019 - pubmed.ncbi.nlm.nih.gov
Systemic treatment of advanced non-small cell lung cancer (NSCLC) has undergone
remarkable changes in the last decade, with the introduction of targeted therapies and …
remarkable changes in the last decade, with the introduction of targeted therapies and …
Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
D Lavacchi, F Mazzoni, G Giaccone - Drug Design, Development and …, 2019 - go.gale.com
Lung cancer is the leading cause of cancer-related death, with 1.6 million tumor-related
deaths annually worldwide. Non-small cell lung cancer (NSCLC) accounts for nearly 85% of …
deaths annually worldwide. Non-small cell lung cancer (NSCLC) accounts for nearly 85% of …
Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
D Lavacchi, F Mazzoni, G Giaccone - Drug Design, Development …, 2019 - europepmc.org
Systemic treatment of advanced non-small cell lung cancer (NSCLC) has undergone
remarkable changes in the last decade, with the introduction of targeted therapies and …
remarkable changes in the last decade, with the introduction of targeted therapies and …
[引用][C] Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
D Lavacchi, F Mazzoni, G Giaccone - Drug Design, Development and …, 2019 - cir.nii.ac.jp
<p>Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer
(NSCLC): current perspectives</p> | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
(NSCLC): current perspectives</p> | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
D Lavacchi, F Mazzoni… - … Design, Development and …, 2019 - search.proquest.com
Systemic treatment of advanced non-small cell lung cancer (NSCLC) has undergone
remarkable changes in the last decade, with the introduction of targeted therapies and …
remarkable changes in the last decade, with the introduction of targeted therapies and …